The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | What role will zolbetuximab play in treating gastric cancer?
Nataliya Uboha, MD, PhD, UW Carbone Cancer Center, Madison, WI, comments on the potential role of zolbetuximab, an anti-claudin 18.2 monoclonal antibody, in the treatment landscape of gastric and gastroesophageal junction (GEJ) cancer. Whilst nivolumab has been approved for this indication following results from the Phase III CheckMate 649 trial (NCT02872116), zolbetuximab represents an additional option for patients. Dr Uboha also highlights the need for further research comparing the efficacy and toxicity in patients based on PD-L1 or claudin 18.2 expression. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
